Innovative biotech company for the industrial culture of red blood cells from stem cells

ERYPHARM has achieved a revolutionary breakthrough in the mass production of cultured red blood cells, with a view to creating a new blood transfusion product.

As a valuable addition to blood donation, this product notably aims to improve quality of life in patients with hereditary blood disorders and cancer, who require multiple transfusions.

A valuable addition to blood donation

  • To offset risks of shortages (epidemics, aging populations)

  • For greater efficacy, to improve treatment

A revolutionary process

EryPharm is paving the way for a new industrial sector to mass produce cultured red blood cells.

Production

An innovative biological product

Cultured red blood cells fulfil all the criteria for optimum transfusion.

An experienced team

Pioneering researchers with expertise in the field, working side by side with experts in industrial process development.

Follow us on Twitter

Ces BioTech françaises qui ont marqué l’année 2021 https://maddy.news/3pGKqLJ - via @bymaddyness /
🙌🙌#EryPharm et son personnel!